Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial.
Linong Ji, Malik Benamar, Viswanathan Mohan et al.
✦ AI-curated · Sources linked
In 30 seconds
The COMBINE 4 trial evaluated the efficacy and safety of once-weekly IcoSema versus once-daily insulin glargine U100 in adults with type 2 diabetes inadequately controlled on oral medications. This 40-week, multicenter, randomized trial found that IcoSema led to a greater reduction in HbA1c (-3.32 vs -2.44 percentage points) and a decrease in body weight (-0.79 kg vs +3.81 kg), with lower hypoglycemia rates.
Key findings
- IcoSema reduced HbA1c by -3.32 percentage points compared to -2.44 with glargine U100.
- Body weight decreased with IcoSema (-0.79 kg) while it increased with glargine U100 (+3.81 kg).
- The rate of severe hypoglycemia was lower with IcoSema (0.29 vs 0.59 episodes per person-year).
Why it matters
This study highlights the potential of IcoSema as a more effective treatment option for managing type 2 diabetes, particularly in patients who are insulin-naive and not achieving adequate control with oral medications. Improved glycemic control and weight management are critical in reducing long-term complications.